Federal Health Agency Refers Hims & Hers to Justice Department Over Unauthorized GLP-1 Sales
A federal health agency has referred Hims & Hers to the Justice Department over allegations it distributed unauthorized GLP-1 weight-loss treatments under a knockoff program. The referral follows findings that the telehealth provider marketed peptide injections without proper approvals, exposing it to potential civil or criminal charges.
1. Health Agency Referral
A federal health agency has officially referred Hims & Hers to the Justice Department after identifying that the telehealth platform allegedly distributed GLP-1 weight-loss medications without required approvals or certifications. Investigators flagged the company’s knockoff program for marketing peptide injections off-label, prompting the escalation to potential federal enforcement.
2. Legal and Financial Implications
The referral could trigger civil fines or criminal charges if the Justice Department pursues the case, potentially disrupting Hims & Hers’ GLP-1 revenue stream. Investor confidence may waver as the company faces increased compliance costs and uncertainty over pending legal outcomes impacting its valuation.